These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

91 related articles for article (PubMed ID: 12833654)

  • 21. FDA approves Cimzia to treat Crohn's disease.
    Lang L
    Gastroenterology; 2008 Jun; 134(7):1819. PubMed ID: 18474249
    [No Abstract]   [Full Text] [Related]  

  • 22. A randomized, placebo-controlled trial of certolizumab pegol (CDP870) for treatment of Crohn's disease.
    Schreiber S; Rutgeerts P; Fedorak RN; Khaliq-Kareemi M; Kamm MA; Boivin M; Bernstein CN; Staun M; Thomsen OØ; Innes A;
    Gastroenterology; 2005 Sep; 129(3):807-18. PubMed ID: 16143120
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Certolizumab pegol and rheumatoid arthritis. Just another TNF alpha antagonist, no therapeutic advantage.
    Prescrire Int; 2010 Dec; 19(111):279. PubMed ID: 21355379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inflammatory bowel diseases--new therapeutic options].
    Herrlinger K; Stange EF
    Med Klin (Munich); 2008 Feb; 103(2):90-101; quiz 102-3. PubMed ID: 18270665
    [No Abstract]   [Full Text] [Related]  

  • 25. Single molecule measurements of tumor necrosis factor α and interleukin-6 in the plasma of patients with Crohn's disease.
    Song L; Hanlon DW; Chang L; Provuncher GK; Kan CW; Campbell TG; Fournier DR; Ferrell EP; Rivnak AJ; Pink BA; Minnehan KA; Patel PP; Wilson DH; Till MA; Faubion WA; Duffy DC
    J Immunol Methods; 2011 Sep; 372(1-2):177-86. PubMed ID: 21821036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity.
    Vermeire S; Schreiber S; Sandborn WJ; Dubois C; Rutgeerts P
    Clin Gastroenterol Hepatol; 2010 Apr; 8(4):357-63. PubMed ID: 20096379
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The future of inflammatory bowel disease care.
    Sandborn WJ
    Rev Gastroenterol Disord; 2009; 9(3):E69-77. PubMed ID: 19898267
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Maintenance therapy with certolizumab pegol for Crohn's disease.
    Schreiber S; Khaliq-Kareemi M; Lawrance IC; Thomsen OØ; Hanauer SB; McColm J; Bloomfield R; Sandborn WJ;
    N Engl J Med; 2007 Jul; 357(3):239-50. PubMed ID: 17634459
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous CDP870, a PEGylated Fab' fragment of a humanized antitumour necrosis factor antibody, in patients with moderate-to-severe Crohn's disease: an exploratory study.
    Winter TA; Wright J; Ghosh S; Jahnsen J; Innes A; Round P
    Aliment Pharmacol Ther; 2004 Dec; 20(11-12):1337-46. PubMed ID: 15606396
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Early treatment in Crohn's disease: do we have enough evidence to reverse the therapeutic pyramid?
    Fascì Spurio F; Aratari A; Margagnoni G; Doddato MT; Papi C
    J Gastrointestin Liver Dis; 2012 Mar; 21(1):67-73. PubMed ID: 22457862
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Anti-TNF therapy in inflammatory bowel diseases: a huge review.
    Peyrin-Biroulet L
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):233-43. PubMed ID: 20485259
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meta-analysis: the efficacy and safety of certolizumab pegol in Crohn's disease.
    Shao LM; Chen MY; Cai JT
    Aliment Pharmacol Ther; 2009 Mar; 29(6):605-14. PubMed ID: 19183161
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Role of the tumor necrosis factor antagonists in the treatment of inflammatory bowel disease: an update.
    Leso V; Leggio L; Armuzzi A; Gasbarrini G; Gasbarrini A; Addolorato G
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):779-86. PubMed ID: 19786877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review.
    Tracey D; Klareskog L; Sasso EH; Salfeld JG; Tak PP
    Pharmacol Ther; 2008 Feb; 117(2):244-79. PubMed ID: 18155297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Sequential therapies for Crohn's disease: optimizing conventional and biologic strategies.
    Desilva S; Kaplan G; Panaccione R
    Rev Gastroenterol Disord; 2008; 8(2):109-16. PubMed ID: 18641593
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evaluation of the meaningfulness of health-related quality of life improvements as assessed by the SF-36 and the EQ-5D VAS in patients with active Crohn's disease.
    Coteur G; Feagan B; Keininger DL; Kosinski M
    Aliment Pharmacol Ther; 2009 May; 29(9):1032-41. PubMed ID: 19222413
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical trial: the effects of certolizumab pegol therapy on work productivity in patients with moderate-to-severe Crohn's disease in the PRECiSE 2 study.
    Feagan BG; Reilly MC; Gerlier L; Brabant Y; Brown M; Schreiber S
    Aliment Pharmacol Ther; 2010 Jun; 31(12):1276-85. PubMed ID: 20298497
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug approvals: '08 in review. Certolizumab pegol (Cimzia).
    Laustsen G; Carrillo F; Johnson J; Smith C
    Nurse Pract; 2009 Feb; 34(2):26-7. PubMed ID: 19155878
    [No Abstract]   [Full Text] [Related]  

  • 39. Recent advances in the management of Crohn's disease.
    Caprilli R; Angelucci E; Clemente V
    Dig Liver Dis; 2008 Sep; 40(9):709-16. PubMed ID: 18430617
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Drug evaluation: CNTO-1275, a mAb against IL-12/IL-23p40 for the potential treatment of inflammatory diseases.
    Wittig BM
    Curr Opin Investig Drugs; 2007 Nov; 8(11):947-54. PubMed ID: 17979029
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.